Epstein-Barr Virus (EBV) Genome and Expression in Breast Cancer Tissue: Effect of EBV Infection of Breast Cancer Cells on Resistance to Paclitaxel (Taxol)
暂无分享,去创建一个
M. Mathieu | J. Peyrat | K. Takada | I. Joab | M. Podgorniak | S. Mourah | J. Guinebretière | V. Víglaský | Vanessa Ramírez | H. Arbach | Florence Lefeu | N. Bride | Nadia Boualaga | Thomas Bauchet | Jean-Marie Seignerin | Hratch Arbach
[1] J. Zalcberg,et al. Epigenetic changes to the MDR1 locus in response to chemotherapeutic drugs , 2005, Oncogene.
[2] M. Newton,et al. Lack of Association between EBV and Breast Carcinoma , 2005, Cancer Epidemiology Biomarkers & Prevention.
[3] M. Yohe,et al. Fatty Acid Synthase Expression Is Induced by the Epstein-Barr Virus Immediate-Early Protein BRLF1 and Is Required for Lytic Viral Gene Expression , 2004, Journal of Virology.
[4] S. D. Hayward,et al. Lytic Viral Replication as a Contributor to theDetection of Epstein-Barr Virus in BreastCancer , 2003, Journal of Virology.
[5] Fabien Calvo,et al. Regulation of extracellular matrix metalloproteinase inducer and matrix metalloproteinase expression by amphiregulin in transformed human breast epithelial cells. , 2003, Cancer research.
[6] Susan Band Horwitz,et al. Mechanisms of Taxol resistance related to microtubules , 2003, Oncogene.
[7] T. Turpeenniemi‐Hujanen,et al. Matrix metalloproteinase-2 (MMP-2) is associated with survival in breast carcinoma , 2003, British Journal of Cancer.
[8] L. Young,et al. Epstein–Barr virus and oncogenesis: from latent genes to tumours , 2003, Oncogene.
[9] B E Griffin,et al. Epstein–Barr virus gene expression in human breast cancer: protagonist or passenger? , 2003, British Journal of Cancer.
[10] Andrew Bell,et al. Reactivity with A monoclonal antibody to Epstein-Barr virus (EBV) nuclear antigen 1 defines a subset of aggressive breast cancers in the absence of the EBV genome. , 2003, Cancer research.
[11] J. Pagano,et al. Epstein-Barr virus induces invasion and metastasis factors. , 2003, Anticancer research.
[12] L. Young,et al. Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma – authors' response , 2003, Breast Cancer Research.
[13] M. Raphaël,et al. Heterogeneous Epstein-Barr virus latent gene expression in AIDS-associated lymphomas and in type I Burkitt's lymphoma cell lines. , 2003, The Journal of general virology.
[14] S. Raguz,et al. P-glycoprotein (MDR1) Expression in Leukemic Cells Is Regulated at Two Distinct Steps, mRNA Stabilization and Translational Initiation* , 2003, The Journal of Biological Chemistry.
[15] G. Niedobitek,et al. Lack of evidence for an association of Epstein–Barr virus infection with breast carcinoma , 2002, Breast Cancer Research.
[16] T. Yoshizaki,et al. Epstein-barr virus latent membrane protein 1 induces and causes release of fibroblast growth factor-2. , 2002, Cancer research.
[17] U. Lehmann,et al. Marked Intratumoral Heterogeneity of c-myc and CyclinD1 But Not of c-erbB2 Amplification in Breast Cancer , 2002, Laboratory Investigation.
[18] R. Longnecker,et al. Lack of Expression of the Epstein-Barr Virus (EBV) Gene Products, EBERs, EBNA1, LMP1, and LMP2A, in Breast Cancer Cells , 2002, Laboratory Investigation.
[19] S. Tsutsui,et al. EGFR, c-erbB2 and p53 protein in the primary lesions and paired metastatic regional lymph nodes in breast cancer. , 2002, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.
[20] K. Brengel-Pesce,et al. Routine use of real‐time quantitative PCR for laboratory diagnosis of Epstein‐Barr virus infections , 2002, Journal of medical virology.
[21] P. Chu,et al. No significant association of Epstein-Barr virus infection with invasive breast carcinoma. , 2001, The American journal of pathology.
[22] T. Yoshizaki,et al. Induction of cyclooxygenase-2 by Epstein–Barr virus latent membrane protein 1 is involved in vascular endothelial growth factor production in nasopharyngeal carcinoma cells , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[23] G. Inman,et al. Activators of the Epstein-Barr Virus Lytic Program Concomitantly Induce Apoptosis, but Lytic Gene Expression Protects from Cell Death , 2001, Journal of Virology.
[24] F. Spyratos,et al. Frequency and genome load of Epstein-Barr virus in 509 breast cancers from different geographical areas , 2001, British Journal of Cancer.
[25] K. Kuroiwa,et al. MDR1 gene overexpression and altered degree of methylation at the promoter region in bladder cancer during chemotherapeutic treatment. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[26] F. Révillion,et al. Prognostic value of the type I growth factor receptors in a large series of human primary breast cancers quantified with a real-time reverse transcription-polymerase chain reaction assay. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.
[27] E. Kremmer,et al. Detection of Epstein-Barr virus in invasive breast cancers. , 1999, Journal of the National Cancer Institute.
[28] W. Kaufmann,et al. The Epstein-Barr Virus Protein BRLF1 Activates S Phase Entry through E2F1 Induction , 1999, Journal of Virology.
[29] T. Yoshizaki,et al. Matrix metalloproteinase 9 is induced by the Epstein–Barr virus BZLF1 transactivator , 1999, Clinical & Experimental Metastasis.
[30] K. Takada,et al. Cell-to-Cell Contact as an Efficient Mode of Epstein-Barr Virus Infection of Diverse Human Epithelial Cells , 1998, Journal of Virology.
[31] D. Martel-Renoir,et al. Amino‐acid change in the Epstein‐Barr‐virus zebra protein in undifferentiated nasopharyngeal carcinomas from Europe and North Africa , 1998, International journal of cancer.
[32] E. Kremmer,et al. IN SITU DETECTION OF THE EPSTEIN–BARR VIRUS‐ENCODED NUCLEAR ANTIGEN 1 IN ORAL HAIRY LEUKOPLAKIA AND VIRUS‐ASSOCIATED CARCINOMAS , 1996, The Journal of pathology.
[33] S. Shousha,et al. Presence of epstein-barr-virus in breast-carcinoma. , 1995, International journal of oncology.
[34] D. Thorley-Lawson,et al. A novel form of Epstein-Barr virus latency in normal B cells in vivo , 1995, Cell.
[35] Q. Zhang,et al. Functional and physical interaction between p53 and BZLF1: implications for Epstein-Barr virus latency , 1994, Molecular and cellular biology.
[36] M. Blanar,et al. The bZIP transactivator of Epstein-Barr virus, BZLF1, functionally and physically interacts with the p65 subunit of NF-kappa B , 1994, Molecular and cellular biology.
[37] D. Martel-Renoir,et al. Expression of the Epstein-Barr virus immediate early gene, BZLF1, in nasopharyngeal carcinoma tumor cells. , 1993, Virology.
[38] M. Blankenstein. Comparison of ligand binding assay and enzyme immunoassay of oestrogen receptor in human breast cancer cytosols , 1990, Breast Cancer Research and Treatment.
[39] J. Lawrence,et al. Sensitive, high-resolution chromatin and chromosome mapping in situ: Presence and orientation of two closely integrated copies of EBV in a lymphoma line , 1988, Cell.
[40] S Friedman,et al. The importance of histologic grade in long-term prognosis of breast cancer: a study of 1,010 patients, uniformly treated at the Institut Gustave-Roussy. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[41] M. Brigden,et al. Multiple microsample analysis of intratumor estrogen receptor distribution in breast cancers by a combined biochemical/immunohistochemical method. , 1987, European journal of cancer & clinical oncology.
[42] U. Landegren. Measurement of cell numbers by means of the endogenous enzyme hexosaminidase. Applications to detection of lymphokines and cell surface antigens. , 1984, Journal of immunological methods.
[43] M. Olivé,et al. Breast tumor cell lines from pleural effusions. , 1974, Journal of the National Cancer Institute.
[44] E. Kieff. Epstein-Barr virus and its replication , 1996 .
[45] B E Griffin,et al. Epstein-Barr virus in epithelial cell tumors: a breast cancer study. , 1995, Cancer research.
[46] M. Blanar,et al. The bZIP Transactivator of Epstein-Barr Virus, BZLF1, Functionally and Physically Interacts with the p65 Subunit of NF-KB , 2022 .